Skip to main content
Top
Published in: International Journal of Hematology 3/2016

01-09-2016 | Original Article

Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization

Authors: Natsuko Takahashi, Junichi Kameoka, Naoto Takahashi, Yoshiko Tamai, Kazunori Murai, Riko Honma, Hideyoshi Noji, Hisayuki Yokoyama, Yasuo Tomiya, Yuichi Kato, Kenichi Ishizawa, Shigeki Ito, Yoji Ishida, Kenichi Sawada, Hideo Harigae

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

There have been no studies on the distribution of causes of macrocytic anemia with respect to mean corpuscular volume (MCV) cutoff values. We retrospectively investigated the causes of macrocytic anemia (MCV ≥100 fL) among 628 patients who visited the outpatient hematology clinic in Tohoku University Hospital. To ensure data validity, we also analyzed data from 307 patients in eight other hospitals in the Tohoku district. The leading causes of macrocytic anemia (number of patients, %) were myelodysplastic syndromes (121, 19.3 %), suspected bone marrow failure syndromes (BMF; 74, 11.8 %), aplastic anemia (51, 8.1 %), plasma cell dyscrasia (45, 7.2 %), and vitamin B12 deficiency (40, 6.4 %) in Tohoku University Hospital. We made three primary findings as follows. First, the most common cause of macrocytic anemia is BMF. Second, lymphoid and solid malignancies are also common causes of macrocytosis. Third, macrocytic anemia may be classified into three groups: Group 1 (megaloblastic anemia and medications), which can exceed MCV 130 fL; Group 2 (alcoholism/liver disease, BMF, myeloid malignancy, and hemolytic anemia), which can exceed MCV 114 fL; and Group 3 (lymphoid malignancy, chronic renal failure, hypothyroidism, and solid tumors), which does not exceed MCV 114 fL. These conclusions were supported by the results from eight other hospitals.
Literature
1.
go back to reference Wintrobe MM. Classification of the anemias on the basis of differences in the size and hemoglobin content of the red corpuscles. Proc Soc Exp Biol Med. 1930;27:1071–3.CrossRef Wintrobe MM. Classification of the anemias on the basis of differences in the size and hemoglobin content of the red corpuscles. Proc Soc Exp Biol Med. 1930;27:1071–3.CrossRef
2.
go back to reference Babior BM, Bunn HF. Megaloblastic anemia. In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS, editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 601–5. Babior BM, Bunn HF. Megaloblastic anemia. In: Kasper DL, Braunwald E, Hauser S, Longo D, Jameson JL, Fauci AS, editors. Harrison’s principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 601–5.
3.
go back to reference Schnall SF, Berliner N, Duffy TP, Benz Jr. EJ. Approach to the Adult and Child with Anemia. In: Hoffman R, Benz Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LD, et al. editors. Hematology. Basic principles and practice. 3rd ed. New York: Churchill Livingstone; 2000. pp. 367–82 Schnall SF, Berliner N, Duffy TP, Benz Jr. EJ. Approach to the Adult and Child with Anemia. In: Hoffman R, Benz Jr. EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LD, et al. editors. Hematology. Basic principles and practice. 3rd ed. New York: Churchill Livingstone; 2000. pp. 367–82
4.
go back to reference Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin N Am. 1992;76:581–97.CrossRefPubMed Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin N Am. 1992;76:581–97.CrossRefPubMed
5.
go back to reference Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Phys. 2009;79:203–8. Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Phys. 2009;79:203–8.
6.
go back to reference Hattersly PG. Macrocytosis of the erythrocytes: a preliminary report. JAMA. 1964;189:997–9. Hattersly PG. Macrocytosis of the erythrocytes: a preliminary report. JAMA. 1964;189:997–9.
8.
go back to reference Breedveld FC, Bieger R, van Wermeskerken RK. The clinical significance of macrocytosis. Acta Med Scand. 1981;209:319–22.CrossRefPubMed Breedveld FC, Bieger R, van Wermeskerken RK. The clinical significance of macrocytosis. Acta Med Scand. 1981;209:319–22.CrossRefPubMed
9.
go back to reference Keenan WF Jr. Macrocytosis as an indicator of human disease. J Am Board Fam Pract. 1989;2:252–6.PubMed Keenan WF Jr. Macrocytosis as an indicator of human disease. J Am Board Fam Pract. 1989;2:252–6.PubMed
10.
go back to reference Anttila P, Ihalainen J, Salo A, Heiskanen M, Juvonen E, Palotie A. Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. Br J Haematol. 1995;90:797–803.CrossRefPubMed Anttila P, Ihalainen J, Salo A, Heiskanen M, Juvonen E, Palotie A. Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. Br J Haematol. 1995;90:797–803.CrossRefPubMed
11.
go back to reference Mahmoud MY, Lugon M, Anderson CC. Unexplained macrocytosis in elderly patients. Age Ageing. 1996;25:310–2.CrossRefPubMed Mahmoud MY, Lugon M, Anderson CC. Unexplained macrocytosis in elderly patients. Age Ageing. 1996;25:310–2.CrossRefPubMed
12.
go back to reference Seppä K, Heinila K, Sillanaukee P, Saarni M. Evaluation of macrocytosis by general practitioners. J Stud Alcohol. 1996;57:97–100.CrossRefPubMed Seppä K, Heinila K, Sillanaukee P, Saarni M. Evaluation of macrocytosis by general practitioners. J Stud Alcohol. 1996;57:97–100.CrossRefPubMed
13.
go back to reference Savage DG, Ogundipe A, Allen RH, Stabler SP, Lindenbaum J. Etiology and diagnostic evaluation of macrocytosis. Am J Med Sci. 2000;319:343–52.CrossRefPubMed Savage DG, Ogundipe A, Allen RH, Stabler SP, Lindenbaum J. Etiology and diagnostic evaluation of macrocytosis. Am J Med Sci. 2000;319:343–52.CrossRefPubMed
15.
go back to reference Younes M, Dagher GA, Dulanto JV, Njeim M, Kuriakose P. Unexplained macrocytosis. South Med J. 2013;106:121–5.CrossRefPubMed Younes M, Dagher GA, Dulanto JV, Njeim M, Kuriakose P. Unexplained macrocytosis. South Med J. 2013;106:121–5.CrossRefPubMed
16.
go back to reference Veda P. Evaluation of macrocytosis in routine hemograms. Indian J Hematol Blood Transfus. 2013;29:26–30.CrossRefPubMed Veda P. Evaluation of macrocytosis in routine hemograms. Indian J Hematol Blood Transfus. 2013;29:26–30.CrossRefPubMed
17.
go back to reference Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol. 1986;85:337–41.CrossRefPubMed Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol. 1986;85:337–41.CrossRefPubMed
18.
go back to reference Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555–65.PubMed Charache S, Dover GJ, Moore RD, Eckert S, Ballas SK, Koshy M, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79:2555–65.PubMed
19.
go back to reference Higuchi S, Matsushita S, Murayama M, Takagi S, Hayashida M. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry. 1995;152:1219–21.CrossRefPubMed Higuchi S, Matsushita S, Murayama M, Takagi S, Hayashida M. Alcohol and aldehyde dehydrogenase polymorphisms and the risk for alcoholism. Am J Psychiatry. 1995;152:1219–21.CrossRefPubMed
20.
go back to reference Burgstaller S, Wiesinger P, Stauder R. Myelodysplastic syndromes in the elderly: treatment options and personalized management. Drugs Aging. 2015;32:891–905.CrossRefPubMed Burgstaller S, Wiesinger P, Stauder R. Myelodysplastic syndromes in the elderly: treatment options and personalized management. Drugs Aging. 2015;32:891–905.CrossRefPubMed
21.
go back to reference Planche V, Georgin-Lavialle S, Avillach P, Ranque B, Pavie J, Caruba T, et al. Etiologies of diagnostic work-up of extreme macrocytosis defined by an erythrocyte mean corpuscular volume over 130 fL: a study of 109 patients. Am J Hematol. 2014;89:665–6.CrossRefPubMed Planche V, Georgin-Lavialle S, Avillach P, Ranque B, Pavie J, Caruba T, et al. Etiologies of diagnostic work-up of extreme macrocytosis defined by an erythrocyte mean corpuscular volume over 130 fL: a study of 109 patients. Am J Hematol. 2014;89:665–6.CrossRefPubMed
22.
go back to reference Seppä K, Laippala P, Saarni M. Macrocytosis as a consequence of alcohol abuse among patients in general practice. Alcohol Clin Exp Res. 1991;15:871–6.CrossRefPubMed Seppä K, Laippala P, Saarni M. Macrocytosis as a consequence of alcohol abuse among patients in general practice. Alcohol Clin Exp Res. 1991;15:871–6.CrossRefPubMed
23.
go back to reference Isomura S, Mizogami M. The low rate of HIV infection in Japanese homosexual and bisexual men: an analysis of HIV seroprevalence and behavioural risk factors. AIDS. 1992;6:501–3.PubMed Isomura S, Mizogami M. The low rate of HIV infection in Japanese homosexual and bisexual men: an analysis of HIV seroprevalence and behavioural risk factors. AIDS. 1992;6:501–3.PubMed
24.
go back to reference Tennankore KK, Soroka SD, West KA, Kiberd BA. Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study. BMC Nephrol. 2011;11:12–9. Tennankore KK, Soroka SD, West KA, Kiberd BA. Macrocytosis may be associated with mortality in chronic hemodialysis patients: a prospective study. BMC Nephrol. 2011;11:12–9.
26.
go back to reference Zhou X, Meng Y. Association between serum folate level and cervical cancer: a meta-analysis. Arch Gynecol Obstet. 2016;293:871–7.CrossRefPubMed Zhou X, Meng Y. Association between serum folate level and cervical cancer: a meta-analysis. Arch Gynecol Obstet. 2016;293:871–7.CrossRefPubMed
27.
go back to reference Yokoyama A, Yokoyama T, Muramatsu T, Omori T, Matsushita S, Higuchi S, Yokoyama A, et al. Macrocytosis, a new predictor for esophageal squamous cell carcinoma in Japanese alcoholic men. Carcinogenesis. 2003;24:1773–8.CrossRefPubMed Yokoyama A, Yokoyama T, Muramatsu T, Omori T, Matsushita S, Higuchi S, Yokoyama A, et al. Macrocytosis, a new predictor for esophageal squamous cell carcinoma in Japanese alcoholic men. Carcinogenesis. 2003;24:1773–8.CrossRefPubMed
28.
go back to reference Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes’s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222–30.CrossRefPubMed Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes’s original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222–30.CrossRefPubMed
29.
go back to reference Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging. 2014;9:1187–96.PubMedPubMedCentral Bach V, Schruckmayer G, Sam I, Kemmler G, Stauder R. Prevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohort. Clin Interv Aging. 2014;9:1187–96.PubMedPubMedCentral
Metadata
Title
Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization
Authors
Natsuko Takahashi
Junichi Kameoka
Naoto Takahashi
Yoshiko Tamai
Kazunori Murai
Riko Honma
Hideyoshi Noji
Hisayuki Yokoyama
Yasuo Tomiya
Yuichi Kato
Kenichi Ishizawa
Shigeki Ito
Yoji Ishida
Kenichi Sawada
Hideo Harigae
Publication date
01-09-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2043-x

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine